Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
iBio, Inc. Common Stock (IBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IBIO (1-star) is a SELL. SELL since 1 days. Profits (37.68%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.23% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.30M USD | Price to earnings Ratio - | 1Y Target Price 4.3 |
Price to earnings Ratio - | 1Y Target Price 4.3 | ||
Volume (30-day avg) 740495 | Beta -3.37 | 52 Weeks Range 1.50 - 6.89 | Updated Date 01/2/2025 |
52 Weeks Range 1.50 - 6.89 | Updated Date 01/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1948% |
Management Effectiveness
Return on Assets (TTM) -29.73% | Return on Equity (TTM) -84.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35591983 | Price to Sales(TTM) 102.96 |
Enterprise Value 35591983 | Price to Sales(TTM) 102.96 | ||
Enterprise Value to Revenue 94.91 | Enterprise Value to EBITDA -1.59 | Shares Outstanding 9137900 | Shares Floating 6952469 |
Shares Outstanding 9137900 | Shares Floating 6952469 | ||
Percent Insiders 0.14 | Percent Institutions 31.93 |
Analyst Ratings
Rating 5 | Target Price 4.3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
iBio, Inc. Common Stock
Company Overview
History and Background
iBio, Inc. was founded in 2008. Initially focused on plant-based biopharmaceutical manufacturing, it has evolved to offer contract development and manufacturing services and develop its own pipeline of therapeutics.
Core Business Areas
- Contract Development and Manufacturing Organization (CDMO): Provides biopharmaceutical manufacturing services using iBio's FastPharming System, offering speed and flexibility.
- Therapeutics Development: Developing a pipeline of therapeutic candidates targeting diseases like fibrosis and cancer using plant-based expression systems.
Leadership and Structure
Tom Isett is the CEO. The company operates with a management team overseeing various departments including R&D, manufacturing, and business development.
Top Products and Market Share
Key Offerings
- FastPharming System: iBio's proprietary plant-based expression system used for rapid production of recombinant proteins and vaccines. The market share specifically attributable to FastPharming is difficult to isolate as it's embedded in CDMO services and internal programs. Competitors include traditional mammalian cell culture and microbial fermentation-based CDMOs, such as Lonza (LONN.SW) and Catalent (CTLT).
- Therapeutic Pipeline: iBio's pipeline includes candidates targeting fibrosis and cancer. Market share is currently 0% as products are pre-commercial. Competitors depend on the specific therapeutic target, for example: Boehringer Ingelheim in the fibrosis market.
Market Dynamics
Industry Overview
The biopharmaceutical manufacturing industry is experiencing growth due to increasing demand for biologics and personalized medicine. The CDMO segment is driven by the need for specialized expertise and infrastructure.
Positioning
iBio aims to differentiate itself with its FastPharming System, offering speed and cost-effectiveness in protein production. It competes with larger, more established CDMOs but targets niche markets and innovative solutions.
Total Addressable Market (TAM)
The global biopharmaceutical CDMO market is estimated in hundreds of billions of USD and expected to continue growing. iBio, Inc. Common Stock is positioned to capture a portion of this TAM through its proprietary technology.
Upturn SWOT Analysis
Strengths
- FastPharming System for rapid protein production
- Experienced management team
- Strategic partnerships
- Dedicated manufacturing facility
Weaknesses
- Limited financial resources compared to larger CDMOs
- Dependence on successful development of therapeutic pipeline
- Relatively smaller scale CDMO operations
Opportunities
- Growing demand for biosimilars
- Expansion of CDMO services
- Strategic acquisitions
- Development of novel therapeutics
Threats
- Competition from established CDMOs
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn affecting R&D spending
Competitors and Market Share
Key Competitors
- Lonza (LONN.SW)
- Catalent (CTLT)
- Samsung Biologics (207940.KS)
- Emergent BioSolutions (EBS)
Competitive Landscape
iBio faces intense competition from larger CDMOs with greater resources and established client relationships. Its FastPharming System offers a potential competitive advantage, but needs to demonstrate consistent performance and scalability.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: iBio's growth has been driven by securing CDMO contracts and advancing its therapeutic pipeline. Historical revenue growth has been variable.
Future Projections: Analyst projections vary widely, depending on the company's success in securing contracts and advancing its pipeline. Future growth remains uncertain and contingent on pipeline progress and CDMO wins.
Recent Initiatives: Recent initiatives include expanding CDMO capacity, strategic partnerships for technology development, and advancement of therapeutic candidates into clinical trials.
Summary
iBio is a biopharmaceutical company with a focus on plant-based manufacturing, offering both CDMO services and developing its own therapeutics. The FastPharming System provides a competitive edge, but iBio faces financial challenges and competition from larger companies. The company's future depends on successfully securing CDMO contracts, advancing its pipeline, and managing its financial resources effectively. Pipeline risk remains a key consideration.
Similar Companies
CTLT
Catalent Inc
CTLT
Catalent Inc
EBS
Emergent Biosolutions Inc
EBS
Emergent Biosolutions Inc
LGND
Ligand Pharmaceuticals Incorporated
LGND
Ligand Pharmaceuticals Incorporated
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Third-party financial data providers
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The market share data is based on estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iBio, Inc. Common Stock
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2008-08-19 | CEO, Chief Scientific Officer & Director Dr. Martin B. Brenner D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://ibioinc.com |
Full time employees 16 | Website https://ibioinc.com | ||
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.